

Sun Pharmaceutical Industries Ltd.,  
SUN HOUSE, CTS No. 201 B/1,  
Western Express HI Highway, Goregaon(E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**8 December 2022.**

National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

BSE Limited,  
Market Operations Dept.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sirs,

**Sub: Update on Halol facility**

This is with respect to our communication dated May 10, 2022 and August 13, 2022 regarding the USFDA inspection at the Company's Halol (Gujarat) facility from April 26 to May 9, 2022.

We now wish to inform you that the Company has received a communication from the USFDA stating that the facility has been listed under Import Alert. The Import Alert implies interalia, that all future shipments of products manufactured at this facility are subject to refusal of admission to the US market until the facility becomes compliant with cGMP standards. The USFDA has excluded 14 products from this Import Alert subject to certain conditions.

For the year ended 31-March-2022, supplies to the US market from the Halol facility accounted for approximately 3% of the Company's consolidated revenues, including the 14 excluded products as mentioned above. The Company continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company's remedial action.

Sun Pharma remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

This is for your information and dissemination.

Thanking you,

Yours faithfully,  
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary & Compliance Officer**